Is Buying Atara Biotherapeutics Inc (NASDAQ:ATRA), Having Lower Short Interest a Winning Strategy?

November 10, 2018 - By Marie Mckinney

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Logo

Investors sentiment decreased to 1.89 in Q2 2018. Its down 1.97, from 3.86 in 2018Q1. It fall, as 11 investors sold Atara Biotherapeutics, Inc. shares while 26 reduced holdings. 19 funds opened positions while 51 raised stakes. 44.51 million shares or 46.45% less from 83.11 million shares in 2018Q1 were reported.
Parametric Associates Ltd Liability has invested 0% of its portfolio in Atara Biotherapeutics, Inc. (NASDAQ:ATRA). 6.25 million were accumulated by Baupost Group Ltd Liability Corporation Ma. The California-based Schwab Charles Inv has invested 0.01% in Atara Biotherapeutics, Inc. (NASDAQ:ATRA). Manufacturers Life Insur The holds 0% or 29,969 shares. Pacific Heights Asset Mngmt Ltd Liability Co stated it has 125,000 shares. Citadel Ltd reported 5,683 shares. Riverhead Cap Lc holds 3,023 shares or 0% of its portfolio. Dimensional Fund Advsr Limited Partnership has invested 0% in Atara Biotherapeutics, Inc. (NASDAQ:ATRA). Wells Fargo And Mn holds 0% or 386,672 shares. Neuberger Berman Grp Limited Liability Corporation reported 1.14 million shares stake. Fmr Ltd Limited Liability Company accumulated 6.13M shares. Bnp Paribas Arbitrage Sa stated it has 1,579 shares. Goldman Sachs Group reported 422,103 shares. Voya Investment Mngmt Ltd Liability invested 0% of its portfolio in Atara Biotherapeutics, Inc. (NASDAQ:ATRA). Great West Life Assurance Com Can reported 3,309 shares.

Since May 14, 2018, it had 1 insider buy, and 17 selling transactions for $8.28 million activity. $283,647 worth of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) was sold by Ciechanover Isaac E. on Monday, August 20. Another trade for 2,000 shares valued at $73,600 was bought by Koppikar Utpal. Newell Joe sold $56,610 worth of stock. $535,301 worth of stock was sold by Fust Matthew K on Monday, May 14. 273 shares were sold by Gallagher Carol Giltner, worth $12,574. Haqq Christopher sold $1.17M worth of stock.

The stock of Atara Biotherapeutics Inc (NASDAQ:ATRA) registered a decrease of 3.25% in short interest. ATRA’s total short interest was 6.19M shares in November as published by FINRA. Its down 3.25% from 6.39M shares, reported previously. With 515,100 shares average volume, it will take short sellers 12 days to cover their ATRA’s short positions. The short interest to Atara Biotherapeutics Inc’s float is 21.41%.

The stock decreased 4.23% or $1.6 during the last trading session, reaching $36.23. About 706,880 shares traded or 22.39% up from the average. Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has risen 165.68% since November 10, 2017 and is uptrending. It has outperformed by 150.06% the S&P500.

Atara Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for patients with severe and life-threatening diseases in the United States. The company has market cap of $1.64 billion. The Company’s clinical stage T-cell product candidates include ATA129 that focuses on Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus associated post-transplant lymphoproliferative disorder after hematopoietic cell transplant and solid organ transplant; ATA188, which is in Phase I clinical trial for the treatment of multiple sclerosis; ATA520, a Phase I clinical trial product targeting cancers expressing the antigen Wilms tumor 1; and ATA230, which is Phase III clinical trials for refractory cytomegalovirus. It currently has negative earnings. The firm is also developing a next generation of allogeneic T-cell product candidates utilizing a technology to selectively enhance a T-cellÂ’s ability to target specific viral proteins implicated in disease.

Another recent and important Atara Biotherapeutics, Inc. (NASDAQ:ATRA) news was published by which published an article titled: “ATARA Biotherapeutics (ATRA) Announces Presentations at ASH” on November 01, 2018.

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: